Joseph M. Gozgit

The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors

Michael Hedvat, Dennis Huszar, Andreas Herrmann et al. · Cancer Cell · 2009 · 526 citations · Full text

Tumor Biology, Signaling Pathway, Solid Tumors +8

Ponatinib (AP24534), a Multitargeted Pan-FGFR Inhibitor with Activity in Multiple FGFR-Amplified or Mutated Cancer Models

Joseph M. Gozgit, Matthew J. Wong, Lauren Moran et al. · Molecular Cancer Therapeutics · 2012 · 317 citations · Full text

PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity

Joseph M. Gozgit, Melissa M. Vasbinder, Ryan Abo et al. · Cancer Cell · 2021 · 171 citations

Cytokine, Cancer Immunosurveillance, Medicine +9

Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients

Andrew P. Garner, Joseph M. Gozgit, Rana Anjum et al. · Clinical Cancer Research · 2014 · 158 citations

Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies

Joseph M. Gozgit, Matthew J. Wong, Scott Wardwell et al. · Molecular Cancer Therapeutics · 2011 · 151 citations · Full text

Hematological Malignancy, Vitro Inhibitory Activity, Mutant Bcr-abl +15